Lipocine Inc. — FY 2018 Form 10-K
Reporting period: Year ended December 31, 2018; filed March 6, 2019. The filing also reports fourth-quarter results. Lipocine is a pre-commercial specialty pharmaceutical company developing oral drug-delivery products, led by TLANDO, an oral testosterone replacement therapy. It has not generated product-sale revenue.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $428,000, all license revenue | $0 |
| Research and development expense | $6.46 million | $11.00 million |
| General and administrative expense | $5.29 million | $10.21 million |
| Operating loss | $11.33 million | $21.22 million |
| Net loss | $11.66 million | $20.98 million |
| Basic and diluted loss per share | $0.55 | $1.05 |
| Cash used in operating activities | $12.08 million | $16.70 million |
- FY 2018 fourth-quarter operating loss was $3.17 million and net loss was $3.23 million.
- At year-end, cash and cash equivalents were $8.08 million, marketable securities were $7.17 million, and restricted cash was $5.00 million. Management’s reported unrestricted cash, cash equivalents and marketable securities totaled $15.3 million.
- Total assets were $20.85 million, total liabilities $11.42 million, and stockholders’ equity $9.43 million. Accumulated deficit was $138.1 million.
- Debt originated with a $10.0 million Silicon Valley Bank loan; the balance sheet reports $10.26 million including the accrued final-payment charge. Interest was prime plus 1% (6.5% at year-end); the loan matures December 2021. The $5.0 million restricted cash collateral remains required until TLANDO receives FDA approval.
- Management estimated existing resources would fund projected operating requirements through at least March 31, 2020, but said additional capital would ultimately be needed. In the first quarter of 2019, the company raised about $4.4 million net through its ATM offering.
Margins are not meaningful for this pre-revenue business. The filing reports no off-balance-sheet arrangements.
Material changes and operating developments
- Net loss narrowed by about $9.3 million year over year as R&D and G&A spending fell. R&D declined primarily because TLANDO’s dosing studies were completed in 2017; G&A declined with lower personnel, pre-commercialization, professional-fee and litigation-settlement costs.
- Operating cash use decreased by about $4.6 million. Financing included the $10.0 million SVB loan and $652,000 net proceeds from 2018 ATM share sales; investment maturities also funded operations.
- TLANDO received a second FDA Complete Response Letter in May 2018. The FDA identified issues concerning possible ex-vivo testosterone conversion in samples, blood-pressure effects, Cmax data, and dose-stopping criteria. The definitive phlebotomy study reported no significant conversion under specified processing conditions. Enrollment in a 138-subject ambulatory blood pressure study was complete; results were expected in Q1 2019.
- Management expected to resubmit the TLANDO NDA around mid-2019 if study findings supported resubmission; any FDA review timeline depends on acceptance. Approval is not assured.
- LPCN 1144’s small proof-of-concept liver-imaging study reported interim results after year-end: among seven evaluable subjects with baseline liver fat of at least 10%, mean liver fat fell 7.6 percentage points (38% relative reduction). The filing cautions these early results may not predict later clinical outcomes. FDA clearance was obtained for a planned Phase 2 study in biopsy-confirmed NASH.
- Management planned to prioritize TLANDO and LPCN 1144 in 2019. It did not anticipate starting Phase 3 studies for LPCN 1111 or LPCN 1107 in 2019 without additional capital or an out-license. No LPCN 1107 licensing agreement had been signed.
Risks, contingencies and unusual items
- Funding and dilution: The company continues to incur losses, has no product revenue, and relies on capital markets or potential licensing and collaboration arrangements. Financing may be unavailable or dilutive; reduced funding could delay or curtail development.
- Regulatory and safety risk: TLANDO has received two CRLs. Blood-pressure findings, FDA requirements, labeling, REMS or further studies could delay or prevent approval. The FDA’s broader TRT safety concerns and competing oral products are additional risks.
- Execution and commercialization: Lipocine has limited staff and no sales force, and depends on third parties for clinical work, active ingredient supply and manufacturing. It has no assurance of market access, reimbursement or successful commercialization.
- Debt and liquidity constraints: SVB covenants restrict certain activities, and default could make debt immediately payable. The loan is secured by substantially all assets other than specified exclusions.
- Legal matters: A securities class-action settlement of $4.3 million was approved and paid in 2018; insurance covered $3.6 million. A shareholder derivative suit filed in February 2019 remained pending, with loss not considered probable or estimable. Clarus appealed the PTAB decision canceling its patent claims; the appeal could affect TLANDO’s patent position.
- Unusual period items: The 2018 results included $428,000 of license revenue from related-party Spriaso. Lipocine disclosed ongoing service arrangements with Spriaso, an entity majority-owned by certain current and former directors and affiliates. The company also reports a perpetual 1% royalty to Abbott on future TLANDO net sales, subject to stated limits and generic-related reductions.
Key facts investors should verify
- Whether the TLANDO blood-pressure study and remaining analyses resolved all FDA CRL deficiencies, and whether the NDA was resubmitted and accepted.
- Current unrestricted liquidity, cash burn, ATM capacity and subsequent financing needs, including the effect of the $5.0 million collateral restriction and SVB repayments.
- Whether LPCN 1144’s preliminary liver-fat findings are confirmed in larger, controlled studies and whether the planned Phase 2 program proceeds.
- Progress and funding plans for LPCN 1111 and LPCN 1107, including any executed licensing or collaboration agreements.
- Outcomes of the derivative litigation and Clarus patent appeal, and any resulting financial or intellectual-property exposure.